NICE recommends dropping two drugs from Cancer Drugs FundBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4562 (Published 18 August 2016) Cite this as: BMJ 2016;354:i4562
- Nigel Hawkes
Two drugs currently provided under the Cancer Drugs Fund (CDF) should cease to be available because they are not cost effective, the National Institute for Health and Care Excellence (NICE) has concluded.
Everolimus for breast cancer (Afinitor, Novartis) and ibrutinib for mantle cell lymphoma (Imbruvica, Janssen) do not meet the grade, says NICE in draft guidance now open for consultation.1 2
Under its new operating model the CDF acts as a gateway fund for new cancer drugs, with NICE calling the shots. In the former model the fund made its own decisions …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial